LMR Partners LLP Sells 121,912 Shares of Amedisys, Inc. (NASDAQ:AMED)

LMR Partners LLP decreased its position in Amedisys, Inc. (NASDAQ:AMED) by 31.6% during the 3rd quarter, Holdings Channel reports. The firm owned 263,546 shares of the health services provider’s stock after selling 121,912 shares during the period. LMR Partners LLP’s holdings in Amedisys were worth $25,435,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. KBC Group NV bought a new stake in shares of Amedisys in the third quarter worth about $63,000. State of New Jersey Common Pension Fund D raised its position in Amedisys by 1.7% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 20,357 shares of the health services provider’s stock valued at $1,965,000 after purchasing an additional 339 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new stake in Amedisys in the 3rd quarter worth approximately $243,000. State of Alaska Department of Revenue grew its position in shares of Amedisys by 7.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 3,782 shares of the health services provider’s stock worth $365,000 after buying an additional 255 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of Amedisys by 20.9% during the third quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after buying an additional 236 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Down 0.3 %

Shares of NASDAQ:AMED opened at $90.05 on Monday. The firm has a market capitalization of $2.95 billion, a P/E ratio of 35.73, a P/E/G ratio of 1.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a 50 day moving average price of $96.04 and a 200-day moving average price of $95.86. Amedisys, Inc. has a 52-week low of $89.55 and a 52-week high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.19). The firm had revenue of $587.67 million during the quarter, compared to analysts’ expectations of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Amedisys’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.98 earnings per share. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target for the company. in a research note on Monday, July 29th. Cantor Fitzgerald restated a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $100.67.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.